Oragenics, Inc.'s Teddy's Pride(R) Oral Care Probiotics for Cats and Dogs Now Available to Canadian Pet Stores Through Rolf C. Hagen Inc.
Sep. 23, 2010 (Business Wire) -- Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) (www.oragenics.com) has announced that its oral care probiotic for pets, Teddy’s Pride® (www.teddyspride.com), will join the diverse array of pet products available to pet stores small and large in Canada through Rolf C. Hagen Inc.
“There is a strong synergy with Hagen’s extensive market penetration throughout Canada, which will be complemented by the new technology of Teddy’s Pride® probiotics for pets’ oral care,” said Gerry David, Executive Vice President, Sales and Marketing for Oragenics.
“We are excited to have the opportunity to introduce this new innovation in oral care from Oragenics to our retail partners, who are continuously on the lookout for new and exciting health products to offer their customers,” said Scott Lyall, National Sales Manager / Directeur National des Ventes.
ProBiora3®, the active ingredient in Oragenics' probiotic products, naturally supports gum and tooth health while freshening breath and whitening teeth. ProBiora3® technology was developed by Oragenics' Chief Scientific Officer, Dr. Jeffrey Hillman, D.M.D., Ph.D., during more than 25 years of research, which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida. This technology has only recently become available to the general public. ProBiora3® contains three strains of beneficial bacteria that help maintain a healthy microbial balance in the mouth. It is 100% natural and is made in the USA in an FDA-registered and GMP-certified facility.
About Oragenics, Inc.
Oragenics is a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, Oragenics is developing its pharmaceutical product candidate, SMaRT Replacement Therapy, and also commercializing its oral probiotic product, ProBiora3. Within antibiotics, Oragenics is developing a pharmaceutical candidate, MU1140-S and intends to use its patented, novel organic chemistry platform to create additional antibiotics for therapeutic use.
About Rolf C. Hagen Inc.
Rolf C. Hagen Inc. is the largest privately run pet product manufacturer and distributor in the world. During the past fifty-five years, Hagen has built a solid reputation for quality and innovation in the industry, and has expanded its Canadian-born business to the international market. Hagen’s customers include both small, local pet stores as well as publicly-owned "box stores" such as Petsmart and Petco. Hagen’s global head office is located in Montreal, Quebec , Canada, and the company wholly owns subsidiaries in the United States, England, France, Germany and Malaysia.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
MEDIA CONTACT: For more information about EvoraPlus, visit www.evoraplus.com. To schedule an interview with Dr. Hillman, contact Jennifer Zimmons at (212) 317-1400 / jzimmons@cooperglobalcommunications.com
For Oragenics, Inc.
Jennifer Zimmons, 212-317-1400
jzimmons@cooperglobalcommunications.com
Source: Business Wire (September 23, 2010 - 8:10 AM EDT)
News by QuoteMedia
www.quotemedia.com
